Neurogene (NGNE) Preferred Dividend Payments (2013 - 2014)
Neurogene posted quarterly Preferred Dividend Payments of $1.0 for Q2 2014, down 100.0% year-on-year from $42130.0 in Q2 2013, and down 99.99% on a QoQ basis from $19550.0 in Q1 2014.
Neurogene (NGNE) has 2 years of Preferred Dividend Payments data on file, last reported at $1.0 in Q2 2014.
- For the quarter ending Q2 2014, Preferred Dividend Payments fell 100.0% year-over-year to $1.0; the trailing twelve-month figure through Jun 2014 stood at $105988.0 (changed N/A YoY), and the FY2013 full-year result was $123074.0, down 27.05% from the prior year.
- Preferred Dividend Payments for Q2 2014 stood at $1.0, down from $19550.0 in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $44307.0 in Q1 2013 and bottomed at $1.0 in Q2 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Neurogene | 632.14 Mn | 632.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2014 | 1.00 |
| Mar 31, 2014 | 19,550.00 |
| Jun 30, 2013 | 42,130.00 |
| Mar 31, 2013 | 44,307.00 |